Kwality Pharmaceuticals Ltd — Important, 08-05-2026: Company Update

Kwality Pharmaceuticals' credit ratings have been significantly upgraded by ICRA. Its long-term fund-based term loans of 40 Cr are now rated [ICRA]BBB+ (Stable), and long-term/short-term fund/non-fund based limits totaling 160 Cr are rated [ICRA]BBB+ (Stable)/[ICRA]A2. The company has also been removed from the 'Issuer Not Cooperating' category. This positive revision highlights KPL's strong operational track record, robust revenue growth, healthy profitability, and sound financial health. This development indicates improved creditworthiness, potentially benefiting the company's financing prospects.